2019 QSP Symposium

On this page:

Symposium Overview

The symposium brings together scientists interested in quantitative systems pharmacology (QSP) to present and discuss contemporary approaches, including the challenges and opportunities for advancing the science and practice of QSP. It is hoped the symposium serves to stimulate collaborations and synergies amongst its participants to promote discoveries in the field of QSP.

2021 QSP Agenda

2019 QSP Symposium

8:00 a.m. Registration and continental breakfast   
8:45 a.m. Welcome and Introductory Remarks                                   
James Gallo, PharmD, PhD
Empire Innovation Professor, Pharmaceutical Sciences, University at Buffalo

Donald Mager, PharmD, PhD, FCP
Professor, Pharmaceutical Sciences, University at Buffalo
9:00 a.m. Systems Biology Modeling Approaches for Preclinical-to-Clinical Translation
Douglas Lauffenburger
9:45 a.m. OSP Modeling and the Search for Accuracy and Precision: When a lot is not enough
Oleg Milberg
10:30 a.m. Break
10:45 a.m. A Systems Mechanism for KRAS Mutant Allele-Specific Responses to Targeted Therapy
Edward Stites 
11:30 a.m. Trainee Speaker 1
11:30 a.m. Trainee Speaker 2

2019 QSP Speaker Bios

Panagiota (Pegy) Foteinou.

Panagiota (Pegy) Foteinou
Principal QSP Scientist at Sanofi, Translational Informatics/TMED (Translational Medicine)
Presentation Title: Towards a multiscale QSP model of allergic airway inflammation: challenges and opportunities

Pegy is a biomedical engineer and recently moved to Sanofi to lead the systems pharmacology modeling program in immunology.

Alison Hill.

Alison Hill
Research Fellow, Harvard University, Program in Evolutionary Dynamics
Presentation Title: Integrating models of infection, evolution, and pharmacokinetics to optimize HIV treatment and prevention

Alison Hill is a Research Fellow at Harvard University in the evolutionary dynamics program developing mathematical and  computational tools to help us better understand, predict, and   treat infectious diseases, with a particular focus on human viral  infections including HIV/AIDS.

Nina Isoherranen.

Nina Isoherranen
Professor and Associate Chair, Department of Pharmaceutics, University of Washington
Presentation Title: Mechanistic PBPK modeling of renal clearance and parent-metabolite kinetics

Nina Isoherranen is a Professor and Associate Chair in the University of Washington’s department of Pharmaceutics. She conducts translational research in the area of drug metabolism and drug-drug interactions and physiologically based pharmacokinetic (PBPK) modeling.

Ravi Iyengar.

Ravi Iyengar
Professor and Director, Mount Sinai Institute of Systems Biomedicine
Presentation Title: Network and Pathway Analyses for better prediction and understanding of drug action

Ravi Iyengar is a Professor and Director of Mount Sinai’s Institute of Systems Biomedicine. He has been at the forefront of systems biology and development of cell signaling models. His most recent efforts are in the area of model-based prediction of drug toxicity.

Kevin Janes.

Kevin Janes
Professor, Department of Biomedical Engineering, University of Virginia
Presentation Title: Tackling incompletely penetrant onco-phenotypes by stochastic frequency matching

Kevin Janes is a Professor of Biomedical Engineering at the University of Virginia.  He has combined engineering and molecular biology to develop mathematical models in the areas of cancer and infectious diseases.

Feilim Mac Gabhann.

Feilim Mac Gabhann
Associate Professor, Department of Biomedical Engineering, Institute for Computational Medicine, Johns Hopkins University
Presentation Title: Detailed mechanistic modeling of pharmacodynamics: insights for therapies targeting the VEGF receptor system

Feilim Mac Gabhann serves as Associate Professor in the Institute for Computational Medicine, in Biomedical Engineering at Johns   Hopkins University. He develops mechanistic pharmacodynamic models for different types of therapies, including antibodies in cancer, gene therapy in peripheral artery disease, and cell-based HIV therapy.

Brian Schmidt.

Brian Schmidt
Senior Principal Scientist, Quantitative Clinical Pharmacology, Bristol-Myers Squibb
Presentation Title: Addressing Clinical Development Challenges in Immuno-Oncology with QSP Platforms

Brian Schmidt is a Senior Principal Scientist of Quantitative Clinical Pharmacology at Bristol-Myers Squibb. He completed his PhD training in biomedical engineering and since that time has  performed research in QSP, systems biology, and computational biology.  Current research interests include the development of QSP immuno-oncology models, new QSP tools, and algorithms to incorporate richer datasets into the model calibration process to better inform clinical development.